Project description
Pioneering innovations in gene therapy
Gene therapy, once a distant hope, is now a reality with three rAAV gene therapies approved in the EU and over 30 phase III clinical trials underway. However, its broader application is hindered by challenges such as non-automated manufacturing, limited scalability, and high production costs. With the support of the Marie Skłodowska-Curie Actions programme, the GET-IN project brings together a multidisciplinary doctoral network comprising seven academic and eight non-academic partners. With expertise in vectorology, genome editing, and biomanufacturing, GET-IN aims to train 10 doctoral candidates (DCs) to pioneer innovations in gene therapy. Research focuses on optimised bioprocessing, digital simulation, improved vectors, targeted delivery systems, and human organ-on-chip models, promising a transformative leap in the field.
Objective
Gene therapy has transitioned from a distant hope to reality. To date 3 rAAV gene therapies are approved in the EU, >30 phase III clinical trials ongoing, and exciting developments in therapeutic gene editing in the pipeline. However, fundamental limitations in the bioprocessing of gene therapy vectors limit broader application. Manufacturing is not automated, with an open process environment, limited scalability and robustness, and inefficient downstream processing, resulting in huge footprint and exceedingly high cost of goods. The field requires scalable manufacturing technology with modular design to produce high doses for large patient groups at a fraction of cost. Improved delivery approaches with increased specificity and efficacy at lower doses are needed to overcome emerging safety concerns observed in clinical trials. Prediction of therapeutic efficacy in man is challenging due to a species barrier, underlining the need for humanized models to reduce attrition rates in the development pipeline.
To overcome these challenges, innovation driven by multidisciplinary approaches is direly needed. GET-IN is a doctoral network of 7 academic and 8 non-academic partners, with expertise in vectorology, genome editing, process engineering, biomanufacturing and innovative humanized models. Together, they provide an excellent training framework for 10 Doctoral Candidates (DCs) who will be the future innovators in the gene therapy field. Research in GET-IN will investigate disruptive innovations including optimised bioprocessing, digital simulation, novel and improved vectors and genome editors, targeted delivery systems, and human organ-on-chip models for more relevant safety and efficacy evaluation. The joint training programme will emphasise responsible, cooperative research and innovation, creativity, and entrepreneurship to maximize the career potential of the DCs.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- social scienceseconomics and businessbusiness and managementinnovation management
- social scienceseconomics and businessbusiness and managemententrepreneurship
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
- natural sciencesbiological sciencesgeneticsgenomes
You need to log in or register to use this function
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
3000 Leuven
Belgium